Intralawan P, Paupunwatana S
Department of Pediatrics, Chiang Rai Provincial Hospital, Ministry of Public Health, Bangkok, Thailand.
Asian Pac J Allergy Immunol. 1993 Jun;11(1):79-83.
Two hundred twenty-four immune and non-immune adults were systematically assigned to receive a single dose of Nakayama strain JEVAC in one of four study "arms": 0.1 ml ID, 0.2 ml ID (injection of 0.1 ml at two sites), 0.3 ml ID (injection of 0.1 ml at three sites), or 1.0 ml SC. Immune responses after this single dose (in many cases "booster") was assumed to reflect immune responses of a primary series and was assessed qualitatively (percent seroconvertion) and quantitatively (geometric mean titer) a 30 and 90 days post immunization. The results showed that JEVAC given 0.1 ml. ID at two sites is likely to be as immunogenic as 1.0 ml. given SC.
224名免疫和非免疫成年人被系统地分配到四项研究“组”之一中,接受单剂量的中山株日本脑炎疫苗(JEVAC):0.1毫升皮内注射、0.2毫升皮内注射(在两个部位各注射0.1毫升)、0.3毫升皮内注射(在三个部位各注射0.1毫升)或1.0毫升皮下注射。这一单剂量(在许多情况下为“加强”)后的免疫反应被假定反映了初次免疫系列的免疫反应,并在免疫后30天和90天进行了定性(血清转化率百分比)和定量(几何平均滴度)评估。结果表明,在两个部位各注射0.1毫升皮内的JEVAC可能与皮下注射1.0毫升的免疫原性相同。